# Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

> **NCT00496873** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 100 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Cytoxan
- **DRUG:** Nipent
- **DRUG:** Rituxan

## Key facts

- **NCT ID:** NCT00496873
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00496873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00496873, "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00496873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*